Commenting on the U.S. FDA Early Communication, Allergan Inc. Clarifies FDA’s Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) today commented on and provided support for the U.S. Food and Drug Administration’s (FDA) “Early Communication” regarding a safety review of botulinum toxins in the United States.